• 服務熱線

    15021010459
    技術文章
    當前位置:主頁 > 技術文章 > Ariad抗癌藥Iclusig重返市場

    Ariad抗癌藥Iclusig重返市場

    更新時間:2014-01-20 點擊次數:1509

        去年Ariad Pharmaceuticals公司業(yè)績由于主打抗癌藥物Iclusig被緊急下架而遭受重創(chuàng)。公司一度陷入困境并將其在美國的員工裁員160人,約占美 國分部總員工數的40%,以節(jié)省開支。不過現在Ariad Pharmaceuticals公司迎來一絲曙光。公司已經著手將Iclusig重新推向市場。此次Ariad將把Iclusig的適用癥范圍縮小,并在 藥物包裝上標明可能出現的副作用如心臟病、血液凝塊等。不過由于Iclusig適用范圍變小,公司的收入可能也會大受影響。為解決這一問題公司計劃申請重 啟此前被FDA下令暫停的關于Iclusig治療慢性白血病的研究計劃以達到亡羊補牢的作用。

        不過Ariad Pharmaceuticals公司的這一系列舉措能否獲得預期效果還需要等待公司2014年*季度財報公布后才能知曉。

    詳細英文報道:

        Last year, Ariad Pharmaceuticals ($ARIA) watched more than $2.5 billion melt off its market cap when the cancer-fighting Iclusig began a downward spiral that would eventually remove it from the market. But now begins the rebuilding project, as the Cambridge, MA, drugmaker has relaunched its sole product with a lot of ground to make up.

        The drug is now indicated for a smaller group of leukemia patients than before, and it carries a serious boxed warning about the risk of clotting and heart failure that got it pulled from shelves in the fall. But it is for sale, and that puts Ariad in a better place than many predicted at its nadir.

        "We are back on track," CEO Harvey Berger told Bloomberg last month. "We'll enter 2014 largely where we were as we started off the fall in September."

        Of course, that's not entirely the case. Losing more than half of its value forced Ariad to considerably thin its ranks, laying off 40% of its U.S. workforce--or 160 employees--in an effort to save $26 million. Now the company plans to gradually ramp up stateside sales with the help of specialty pharmacy Biologics, Inc., first looking to transition the case-by-case patients who were still using the drug during its marketing hiatus.

        And the company has a long way to go on the R&D side. When the storm over Iclusig began, Ariad was in the process of testing the drug in a broader population, but an FDA-imposed clinical hold led the company to discontinue a Phase III study on patients with newly diagnosed chronic myeloid leukemia and put the brakes on a fleet of Phase II studies designed to expand the drug's market. Berger has said that Ariad is yet to decide just how to move forward with its paused programs.

        Still, the biotech is undeniably sitting prettier than it was just two months ago, and its next big test will come when Q1 sales figures roll in.——(華雅干細胞整理報道)

    2025 版權所有 © 重慶市華雅干細胞技術有限公司  備案號:渝ICP備14000349號-4 sitemap.xml 管理登陸 技術支持:化工儀器網

    地址:重慶市江北區(qū)金渝大道153號8棟20-14 傳真:023-63419626 郵件:sales@ys-bio.com

    重慶市華雅干細胞技術有限公司主要經營干細胞研究 干細胞治療產品 生物試劑 實驗耗材 藥物研發(fā)等產品。

    關注我們

    服務熱線

    400-021-2200

    掃一掃,關注我們

    主站蜘蛛池模板: 国产成人精品日本亚洲专| 91精品一区国产高清在线| 国产成人精品无码免费看| 欧美国产成人精品一区二区三区| 国产欧美亚洲精品A| 免费精品久久久久久中文字幕| 热久久这里只有精品| 国内精品久久久久影院日本| 青青青青久久精品国产h久久精品五福影院1421 | 久久精品国产亚洲一区二区| 日韩精品无码免费一区二区三区| 久久夜色撩人精品国产| 国产精品手机在线观看你懂的 | 一本久久a久久精品亚洲| 国产精品免费久久久久久久久| 国产乱码精品一区二区三区四川人| 久久精品亚洲日本波多野结衣| 亚洲国产精品一区二区第一页免| 国产亚州精品女人久久久久久| 98香蕉草草视频在线精品看| 国产精品福利一区二区久久| 国产欧美精品一区二区三区| 日韩精品极品视频在线观看免费| 亚欧乱色国产精品免费视频| 久久精品无码一区二区三区免费| 国产精品嫩草影院一二三区| 99re只有精品8中文| 99热精品久久只有精品| 亚洲精品理论电影在线观看| 日本精品久久久久中文字幕| 国产精品大白天新婚身材| 国产欧美日韩精品专区| 91麻豆精品国产91久久久久久| 国产成人精品日本亚洲专| 国产成人久久精品一区二区三区 | 精品人妻伦九区久久AAA片69| 桃花岛精品亚洲国产成人| 久久精品成人免费网站| 久久国产成人精品麻豆| 精品999久久久久久中文字幕| 99视频精品全部在线观看|